Nello Mainolfi, CEO of Kymera Therapeutics ($KYMR), sold about $18.7 million in company shares across 13 open market transactions over the past year. His most recent sale occurred on February 25, 2026. These sales rank him 714th among 11,678 insiders in our database by total value sold, above the average of $8.6 million per insider and 6.4 transactions. Mainolfi made no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 2, 2026 | Kymera Therapeutics, Inc. | $KYMR | Mainolfi Nello | Chief Executive Officer | A | Stock Option (Right to Buy) | 215000 | $0.00 | 215,000.0000 | 87,300,286 | 9999.99% | 0.25% |
| Feb. 25, 2026 | Kymera Therapeutics, Inc. | $KYMR | Mainolfi Nello | Chief Executive Officer | S | Common Stock | 1501 | $92.81 | 666,203.0000 | 87,300,286 | 0.22% | 0.00% |
| Feb. 25, 2026 | Kymera Therapeutics, Inc. | $KYMR | Mainolfi Nello | Chief Executive Officer | M | Stock Option (Right to Buy) | 30000 | $0.00 | 245,559.0000 | 87,300,286 | 10.89% | 0.03% |
| Feb. 25, 2026 | Kymera Therapeutics, Inc. | $KYMR | Mainolfi Nello | Chief Executive Officer | S | Common Stock | 8 | $93.49 | 666,195.0000 | 87,300,286 | 0.00% | 0.00% |
| Feb. 25, 2026 | Kymera Therapeutics, Inc. | $KYMR | Mainolfi Nello | Chief Executive Officer | S | Common Stock | 3293 | $91.76 | 667,704.0000 | 87,300,286 | 0.49% | 0.00% |
| Feb. 25, 2026 | Kymera Therapeutics, Inc. | $KYMR | Mainolfi Nello | Chief Executive Officer | S | Common Stock | 5434 | $90.39 | 670,997.0000 | 87,300,286 | 0.80% | 0.01% |
| Feb. 25, 2026 | Kymera Therapeutics, Inc. | $KYMR | Mainolfi Nello | Chief Executive Officer | M | Common Stock | 30000 | $2.08 | 696,195.0000 | 87,300,286 | 4.50% | 0.03% |
| Feb. 25, 2026 | Kymera Therapeutics, Inc. | $KYMR | Mainolfi Nello | Chief Executive Officer | S | Common Stock | 19764 | $89.78 | 676,431.0000 | 87,300,286 | 2.84% | 0.02% |
| Jan. 5, 2026 | Kymera Therapeutics, Inc. | $KYMR | Mainolfi Nello | Chief Executive Officer | M | Stock Option (Right to Buy) | 3118 | $0.00 | 446,882.0000 | 87,300,286 | 0.69% | 0.00% |
| Jan. 5, 2026 | Kymera Therapeutics, Inc. | $KYMR | Mainolfi Nello | Chief Executive Officer | M | Common Stock | 3118 | $32.07 | 666,195.0000 | 87,300,286 | 0.47% | 0.00% |
| Dec. 31, 2025 | Kymera Therapeutics, Inc. | $KYMR | Mainolfi Nello | Chief Executive Officer | M | Common Stock | 30000 | $2.08 | 693,077.0000 | 87,300,286 | 4.52% | 0.03% |
| Dec. 31, 2025 | Kymera Therapeutics, Inc. | $KYMR | Mainolfi Nello | Chief Executive Officer | M | Stock Option (Right to Buy) | 30000 | $0.00 | 275,559.0000 | 87,300,286 | 9.82% | 0.03% |
| Dec. 31, 2025 | Kymera Therapeutics, Inc. | $KYMR | Mainolfi Nello | Chief Executive Officer | S | Common Stock | 6014 | $78.52 | 663,077.0000 | 87,300,286 | 0.90% | 0.01% |
| Dec. 31, 2025 | Kymera Therapeutics, Inc. | $KYMR | Mainolfi Nello | Chief Executive Officer | S | Common Stock | 23986 | $77.95 | 669,091.0000 | 87,300,286 | 3.46% | 0.03% |
| Dec. 17, 2025 | Kymera Therapeutics, Inc. | $KYMR | Mainolfi Nello | Chief Executive Officer | M | Common Stock | 2595 | $38.53 | 663,077.0000 | 87,300,286 | 0.39% | 0.00% |
| Dec. 17, 2025 | Kymera Therapeutics, Inc. | $KYMR | Mainolfi Nello | Chief Executive Officer | M | Stock Option (Right to Buy) | 2595 | $0.00 | 272,505.0000 | 87,300,286 | 0.94% | 0.00% |
| Dec. 8, 2025 | Kymera Therapeutics, Inc. | $KYMR | Mainolfi Nello | Chief Executive Officer | S | Common Stock | 100000 | $89.17 | 660,482.0000 | 87,300,286 | 13.15% | 0.11% |
| Dec. 8, 2025 | Kymera Therapeutics, Inc. | $KYMR | Mainolfi Nello | Chief Executive Officer | M | Stock Option (Right to Buy) | 100000 | $0.00 | 305,559.0000 | 87,300,286 | 24.66% | 0.11% |
| Dec. 8, 2025 | Kymera Therapeutics, Inc. | $KYMR | Mainolfi Nello | Chief Executive Officer | M | Common Stock | 100000 | $2.08 | 760,482.0000 | 87,300,286 | 15.14% | 0.11% |
| Oct. 29, 2025 | Kymera Therapeutics, Inc. | $KYMR | Mainolfi Nello | Chief Executive Officer | S | Common Stock | 24511 | $61.02 | 664,109.0000 | 87,300,286 | 3.56% | 0.03% |
| Oct. 29, 2025 | Kymera Therapeutics, Inc. | $KYMR | Mainolfi Nello | Chief Executive Officer | M | Common Stock | 30000 | $2.08 | 690,482.0000 | 87,300,286 | 4.54% | 0.03% |
| Oct. 29, 2025 | Kymera Therapeutics, Inc. | $KYMR | Mainolfi Nello | Chief Executive Officer | S | Common Stock | 1862 | $59.72 | 688,620.0000 | 87,300,286 | 0.27% | 0.00% |
| Oct. 29, 2025 | Kymera Therapeutics, Inc. | $KYMR | Mainolfi Nello | Chief Executive Officer | S | Common Stock | 3627 | $61.46 | 660,482.0000 | 87,300,286 | 0.55% | 0.00% |
| Oct. 29, 2025 | Kymera Therapeutics, Inc. | $KYMR | Mainolfi Nello | Chief Executive Officer | M | Stock Option (Right to Buy) | 30000 | $0.00 | 405,559.0000 | 87,300,286 | 6.89% | 0.03% |
| Sept. 16, 2025 | Kymera Therapeutics, Inc. | $KYMR | Mainolfi Nello | Chief Executive Officer | S | Common Stock | 30000 | $49.00 | 660,482.0000 | 75,043,991 | 4.34% | 0.04% |
| Sept. 16, 2025 | Kymera Therapeutics, Inc. | $KYMR | Mainolfi Nello | Chief Executive Officer | M | Stock Option (Right to Buy) | 30000 | $0.00 | 435,559.0000 | 75,043,991 | 6.44% | 0.04% |
| Sept. 16, 2025 | Kymera Therapeutics, Inc. | $KYMR | Mainolfi Nello | Chief Executive Officer | M | Common Stock | 30000 | $2.08 | 690,482.0000 | 75,043,991 | 4.54% | 0.04% |
| June 3, 2025 | Kymera Therapeutics, Inc. | $KYMR | Mainolfi Nello | Chief Executive Officer | M | Stock Option (Right to Buy) | 30000 | $0.00 | 465,559.0000 | 75,043,991 | 6.05% | 0.04% |
| June 3, 2025 | Kymera Therapeutics, Inc. | $KYMR | Mainolfi Nello | Chief Executive Officer | M | Common Stock | 30000 | $2.08 | 690,482.0000 | 75,043,991 | 4.54% | 0.04% |
| June 3, 2025 | Kymera Therapeutics, Inc. | $KYMR | Mainolfi Nello | Chief Executive Officer | S | Common Stock | 30000 | $49.00 | 660,482.0000 | 75,043,991 | 4.34% | 0.04% |
| March 3, 2025 | Kymera Therapeutics, Inc. | $KYMR | Mainolfi Nello | Chief Executive Officer | A | Stock Option (Right to Buy) | 365000 | $0.00 | 365,000.0000 | 75,043,991 | 9999.99% | 0.49% |
| Jan. 10, 2025 | Kymera Therapeutics, Inc. | $KYMR | Mainolfi Nello | Chief Executive Officer | M | Stock Option (Right to Buy) | 10000 | $0.00 | 495,559.0000 | 75,043,991 | 2.06% | 0.01% |
| Jan. 10, 2025 | Kymera Therapeutics, Inc. | $KYMR | Mainolfi Nello | Chief Executive Officer | M | Common Stock | 10000 | $2.08 | 659,959.0000 | 75,043,991 | 1.54% | 0.01% |
| July 1, 2024 | Kymera Therapeutics, Inc. | $KYMR | Mainolfi Nello | Chief Executive Officer | M | Common Stock | 18773 | $5.33 | 649,959.0000 | 58,365,499 | 2.97% | 0.03% |
| July 1, 2024 | Kymera Therapeutics, Inc. | $KYMR | Mainolfi Nello | Chief Executive Officer | M | Stock Option (Right to Buy) | 18773 | $0.00 | 288,456.0000 | 58,365,499 | 6.11% | 0.03% |
| June 18, 2024 | Kymera Therapeutics, Inc. | $KYMR | Mainolfi Nello | Chief Executive Officer | M | Stock Option (Right to Buy) | 14413 | $0.00 | 505,559.0000 | 58,365,499 | 2.77% | 0.02% |
| June 18, 2024 | Kymera Therapeutics, Inc. | $KYMR | Mainolfi Nello | Chief Executive Officer | M | Common Stock | 14413 | $2.08 | 631,186.0000 | 58,365,499 | 2.34% | 0.02% |
| March 1, 2024 | Kymera Therapeutics, Inc. | $KYMR | Mainolfi Nello | Chief Executive Officer | A | Stock Option (Right to Buy) | 530000 | $0.00 | 530,000.0000 | 58,365,499 | 9999.99% | 0.91% |
| Jan. 2, 2024 | Kymera Therapeutics, Inc. | $KYMR | Mainolfi Nello | Chief Executive Officer | M | Stock Option (Right to Buy) | 9000 | $0.00 | 519,972.0000 | 58,365,499 | 1.70% | 0.02% |
| Jan. 2, 2024 | Kymera Therapeutics, Inc. | $KYMR | Mainolfi Nello | Chief Executive Officer | M | Common Stock | 9000 | $2.08 | 615,570.0000 | 58,365,499 | 1.48% | 0.02% |
| Nov. 3, 2023 | Kymera Therapeutics, Inc. | $KYMR | Mainolfi Nello | Chief Executive Officer | M | Stock Option (Right to Buy) | 2368 | $0.00 | 0.0000 | 53,933,229 | 100.00% | 0.00% |
| Nov. 3, 2023 | Kymera Therapeutics, Inc. | $KYMR | Mainolfi Nello | Chief Executive Officer | M | Common Stock | 2368 | $2.08 | 588,938.0000 | 53,933,229 | 0.40% | 0.00% |
| Nov. 3, 2023 | Kymera Therapeutics, Inc. | $KYMR | Mainolfi Nello | Chief Executive Officer | M | Common Stock | 17632 | $2.08 | 606,570.0000 | 53,933,229 | 2.99% | 0.03% |
| Nov. 3, 2023 | Kymera Therapeutics, Inc. | $KYMR | Mainolfi Nello | Chief Executive Officer | M | Stock Option (Right to Buy) | 17632 | $0.00 | 528,972.0000 | 53,933,229 | 3.23% | 0.03% |
| Aug. 8, 2023 | Kymera Therapeutics, Inc. | $KYMR | Mainolfi Nello | Chief Executive Officer | M | Stock Option (Right to Buy) | 12000 | $0.00 | 2,368.0000 | 53,933,229 | 83.52% | 0.02% |
| Aug. 8, 2023 | Kymera Therapeutics, Inc. | $KYMR | Mainolfi Nello | Chief Executive Officer | M | Common Stock | 12000 | $2.08 | 586,570.0000 | 53,933,229 | 2.09% | 0.02% |
| March 1, 2023 | Kymera Therapeutics, Inc. | $KYMR | Mainolfi Nello | Chief Executive Officer | A | Stock Option (Right to Buy) | 450000 | $0.00 | 450,000.0000 | 53,933,229 | 9999.99% | 0.83% |